Profile data is unavailable for this security.
About the company
Sareum Holdings plc is a United Kingdom-based biotechnology company. The principal activity of the Company is the discovery and development of new therapeutic drugs using a combination of skills in biology, computational chemistry and medicinal chemistry. The Company's internal programs focus on distinct dual tyrosine kinase 2 (TYK2)/ Janus kinase 1 (JAK1) inhibitors, which are progressing through preclinical development as therapies for autoimmune diseases and cancers. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, with an initial focus on psoriasis. It is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy. The Company also has an interest in SRA737, an orally bioavailable small molecule inhibitor of checkpoint kinase 1 (Chk1), a key regulator of important cell cycle checkpoints and a central mediator of the DNA damage response (DDR) network.
- Revenue in GBP (TTM)0.00
- Net income in GBP-2.76m
- Incorporated2004
- Employees5.00
- LocationSareum Holdings PLCUnit 2ALangford Arch, London Road, PampisfordCAMBRIDGE CB22 3FXUnited KingdomGBR
- Phone+44 122 349 7700
- Fax+44 122 349 7701
- Websitehttps://sareum.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CRUSHMETRIC Group Ltd | 911.68k | -196.15k | 48.03m | 6.00 | -- | -- | -- | 52.68 | -0.0022 | -0.0022 | 0.0104 | -0.0474 | 1.06 | 5.14 | 5.24 | -- | -64.23 | -118.75 | -- | -- | 46.12 | 38.24 | -60.68 | -156.87 | 0.0909 | -10.54 | -- | -- | -75.86 | -14.62 | -156.85 | -- | -- | -- |
| Shield Therapeutics PLC | 4.47m | -40.44m | 48.13m | 23.00 | -- | 3.77 | -- | 10.77 | -0.1661 | -0.1661 | 0.0188 | 0.0179 | 0.1344 | 1.60 | 1.08 | -- | -121.66 | -38.57 | -154.17 | -43.09 | 44.71 | 80.67 | -905.40 | -253.15 | 0.8118 | -- | 0.5291 | -- | 194.08 | 47.63 | -105.53 | -- | -11.08 | -- |
| Venture Life Group PLC | 43.98m | 520.00k | 48.70m | 153.00 | 110.00 | 0.6437 | 8.25 | 1.11 | 0.0035 | 0.0035 | 0.3297 | 0.5981 | 0.3842 | 2.50 | 3.07 | 287,451.00 | 0.4543 | 1.75 | 0.5151 | 2.01 | 40.17 | 40.30 | 1.18 | 4.41 | 1.34 | 2.19 | 0.2619 | 0.00 | 34.24 | 22.33 | -78.35 | -- | 37.59 | -- |
| Spectral MD Holdings Ltd | 20.40m | -2.34m | 61.34m | 71.00 | -- | 6.32 | -- | 3.01 | -0.0173 | -0.0173 | 0.1506 | 0.0712 | 1.36 | -- | 13.61 | 287,283.70 | -15.63 | -- | -22.32 | -- | 42.72 | -- | -11.48 | -- | -- | -12.73 | 0.0788 | -- | 66.47 | -- | 44.50 | -- | -- | -- |
| 4Basebio PLC | 268.00k | -5.15m | 69.61m | -- | -- | 9.77 | -- | 259.72 | -0.4181 | -0.4181 | 0.0218 | 0.578 | -- | -- | -- | -- | -- | -- | -- | -- | 89.18 | -- | -1,921.64 | -- | 3.80 | -65.62 | 0.32 | -- | -20.71 | -- | -59.20 | -- | -- | -- |
| Eco Animal Health Group Plc | 78.58m | 779.00k | 70.77m | 221.00 | 91.67 | 0.8451 | 22.27 | 0.9006 | 0.0114 | 0.0114 | 1.16 | 1.24 | 0.6695 | 1.52 | 2.93 | 355,565.60 | 1.09 | 7.78 | 1.53 | 10.06 | 42.53 | 46.98 | 1.63 | 10.42 | 2.14 | -- | 0.0183 | 53.51 | -22.17 | 6.00 | -109.35 | -- | -18.83 | -- |
| Arecor Therapeutics PLC | 2.40m | -9.26m | 76.55m | 51.00 | -- | 4.39 | -- | 31.85 | -0.3198 | -0.3198 | 0.083 | 0.5701 | 0.1126 | -- | 0.8374 | 47,117.65 | -43.39 | -- | -50.48 | -- | -- | -- | -385.35 | -- | 4.38 | -- | 0.0162 | -- | 107.51 | -- | -50.11 | -- | -- | -- |
| Creo Medical Group PLC | 27.17m | -26.94m | 85.09m | 284.00 | -- | 0.9234 | -- | 3.13 | -0.1434 | -0.1434 | 0.1446 | 0.2626 | 0.3088 | 1.58 | 4.69 | 95,665.49 | -30.62 | -- | -38.83 | -- | 48.30 | -- | -99.14 | -- | 1.39 | -139.17 | 0.1913 | -- | 7.98 | -- | -9.52 | -- | -- | -- |
| Sareum Holdings Plc | 0.00 | -2.76m | 91.89m | 5.00 | -- | 31.85 | -- | -- | -0.0406 | -0.0406 | 0.00 | 0.0424 | 0.00 | -- | -- | 0.00 | -59.88 | -64.34 | -64.48 | -71.09 | -- | -- | -- | -16,059.92 | -- | -- | 0.00 | -- | -- | -- | -44.76 | -- | -28.45 | -- |
| Redx Pharma PLC | 12.65m | -29.01m | 93.78m | 71.00 | -- | 6.28 | -- | 7.41 | -0.0883 | -0.0883 | 0.039 | 0.0446 | 0.3056 | -- | 47.28 | -- | -70.08 | -44.98 | -148.14 | -70.15 | -- | -- | -229.35 | -164.47 | -- | -- | 0.5574 | -- | 86.25 | -9.31 | 16.55 | -- | 11.21 | -- |
| e-Therapeutics plc | 475.00k | -8.27m | 99.20m | 38.00 | -- | 3.00 | -- | 208.84 | -0.0154 | -0.0154 | 0.0009 | 0.0568 | 0.0148 | -- | 1.92 | 12,500.00 | -25.79 | -33.25 | -27.10 | -35.11 | 100.00 | 100.00 | -1,741.90 | -1,490.90 | -- | -- | 0.0089 | -- | -0.4193 | -- | -2.53 | -- | 24.22 | -- |
| Celadon Pharmaceuticals PLC | -100.00bn | -100.00bn | 100.21m | -- | -- | 9.01 | -- | -- | -- | -- | -- | 0.1804 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 6.96 | -- | 0.301 | -- | -- | -- | -- | -- | -- | -- |
| Open Orphan PLC | 48.48m | -776.00k | 104.19m | 235.00 | -- | 5.09 | 48.37 | 2.15 | -0.0012 | -0.0012 | 0.0723 | 0.0301 | 1.04 | -- | 4.44 | 206,285.10 | -1.66 | -15.59 | -3.59 | -31.13 | -- | -- | -1.60 | -17.76 | 1.40 | -- | 0.0718 | -- | 31.50 | 26.01 | -948.65 | -- | 24.47 | -- |
| Animalcare Group Plc | 71.62m | 1.97m | 109.07m | 211.00 | 56.09 | 1.38 | 11.17 | 1.52 | 0.0324 | 0.0324 | 1.18 | 1.31 | 0.6275 | 2.60 | 6.92 | -- | 1.72 | 0.0877 | 2.05 | 0.1026 | 56.77 | 52.29 | 2.74 | 0.1562 | 0.9121 | 7.67 | 0.1265 | 2,045.05 | -3.25 | -- | 2,651.95 | -- | -- | -- |
| Futura Medical PLC | 0.00 | -5.85m | 121.59m | 12.00 | -- | 25.76 | -- | -- | -0.0203 | -0.0203 | 0.00 | 0.0164 | 0.00 | -- | -- | 0.00 | -63.98 | -75.22 | -80.95 | -106.12 | -- | -- | -- | -88,144.94 | -- | -- | 0.00 | -- | -- | -- | -17.93 | -- | 67.85 | -- |
| Scancell Holdings Plc | 0.00 | -8.44m | 126.85m | 40.00 | -- | 8.19 | -- | -- | -0.0104 | -0.0104 | 0.00 | 0.0189 | 0.00 | -- | -- | 0.00 | -20.30 | -31.06 | -21.45 | -33.18 | -- | -- | -- | -- | -- | -19.72 | 0.3805 | -- | -- | -- | 86.66 | -- | 83.42 | -- |
Data as of Jun 06 2023. Currency figures normalised to Sareum Holdings PLC's reporting currency: UK Pound GBX
13.01%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Hargreaves Lansdown Asset Management Ltd.as of 02 Apr 2023 | 4.35m | 6.38% |
| HSBC Global Asset Management (UK) Ltd.as of 02 Apr 2023 | 2.92m | 4.28% |
| Jarvis Investment Management Ltd.as of 02 Apr 2023 | 573.00k | 0.84% |
| IG Markets Ltd.as of 02 Apr 2023 | 451.00k | 0.66% |
| Rowan Dartington & Co. Ltd. (Broker)as of 02 Apr 2023 | 170.00k | 0.25% |
| J. M. Finn & Co. Ltd.as of 02 Apr 2023 | 94.00k | 0.14% |
| Evelyn Partners Investment Management Services Ltd.as of 02 Apr 2023 | 87.00k | 0.13% |
| Walker Crips Investment Management Ltd.as of 02 Apr 2023 | 76.00k | 0.11% |
| iDealing.com Ltd.as of 02 Apr 2023 | 75.00k | 0.11% |
| Eurizon Capital SGR SpAas of 02 Apr 2023 | 66.00k | 0.10% |
More ▼
Data from 31 Mar 2022 - 31 May 2023Source: FactSet Research Systems Inc.
